Solid tumors


In 2008, 21,500 new colorectal cancer cases were reported in Canada and 8,900 patients died from it. In recent years, studies successfully demonstrated that the tumour’s genetic make-up can influence the patient’s response to treatment. More specifically, patients with mutations in the tumour’s k-ras oncogene tend not to respond to anti-EGFR monoclonal antibodies, a class of chemotherapeutic drugs widely used for the treatment of colorectal cancer. Determination of a tumour’s k-ras mutation status has thus become a key component of the oncologist’s treatment plan.

Ordering the test

The Molecular Pathology Unit at the Sir Mortimer B. Davis-Jewish General Hospital provides oncologists with a k-ras mutation detection test performed on DNA extracted from paraffin-embedded tumour tissue.

The oncologist can order the test by filling out the PDF requisition form available below (in French or English). This form can be completed electronically in the free version of Adobe Acrobat; it must then be printed out and faxed to the holding lab. Please keep a copy of the completed form in case it has to be sent back due to missing information.

If you require more information, please contact the reception at 514-340-8222 ext. 4359.

Urothelial Carcinoma FGFR Testing

 Urothelial Carcinoma FGFR Testing REQ.pdf

Page last updated on 

We always seek feedback to make our site better.